ResMed's consistent 7-11% revenue growth, gross margin expansion to 58.4%, and robust cash generation (FCF margin 112.7% in 2026Q4) underscore its market leadership in sleep and respiratory care. However, the recent spike in stock-based compensation to $104.3M...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 8.6% YoY in 2026Q4 to $1.5B, with gross margin at 58.4% (down from 62.2% peak), while operating margin remained strong at 30.7%.
ResMed provides cutting-edge medical devices and cloud-connectable solutions for sleep apnea and respiratory conditions like COPD, improving patient outcomes.
ResMed is a leader in the CPAP industry, known for its innovative, user-friendly, and comfortable products that are trusted worldwide.
The company has a wide moat, supported by its strong brand, innovative technology, and leadership in the sleep apnea and respiratory care markets.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $2.95+2.1% vs $2.89 | $1.5B+0.2% vs $1.5B |
Q2 2026 Apr 30, 2026 | $2.86+2.1% vs $2.80 | $1.4B+0.8% vs $1.4B |
Q1 2026 Jan 29, 2026 | $2.81+2.6% vs $2.74 | $1.4B+1.6% vs $1.4B |
Q4 2025 Oct 30, 2025 | $2.55+1.6% vs $2.51 | $1.3B+0.2% vs $1.3B |
ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell said the company has issued guidance for 5% to 7% core constant-currency revenue growth, including an
ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.
Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 shares of the medical equipment provider's stock after acquiring an additional 3,555 shares during the period. Engineers Gate
Setbacks for competitors have positioned ResMed to capture more market share.
Benchmark RMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ResMed Inc. (RMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $222.30 | $32.25B | — | 9.85% | 26.94% | 24.27% | — | |
| $24.45 | $23.9B | 23.09 | -1.04% | 6.31% | 10.02% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $69.06 | $1.99B | 14.12 | 13.6% | 15.03% | 17.62% | — | |
| $16.38 | $1.12B | -5.39 | 7.93% | -6.08% | -45.97% | — |
ResMed Inc. (RMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ResMed Inc. (RMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Aug 6, 2026·SEC
Jul 7, 2026·SEC
Get notified when RMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ResMed Inc. (RMD) stock FAQ — growth, dividends, profitability & financials explained
ResMed Inc. (RMD) reported $5.65B in revenue for fiscal year 2026. This represents a 11391% increase from $49.2M in 1997.
ResMed Inc. (RMD) grew revenue by 9.9% over the past year. This is steady growth.
Yes, ResMed Inc. (RMD) is profitable, generating $1.52B in net income for fiscal year 2026 (26.9% net margin).
ResMed Inc. (RMD) has a return on equity (ROE) of 24.3%. This is excellent, indicating efficient use of shareholder capital.
ResMed Inc. (RMD) generated $2.89B in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
